CTI-1601
Sponsors
Larimar Therapeutics, Inc.
Conditions
Friedreich Ataxia
Phase 1
Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
CompletedNCT04176991
Start: 2019-12-11End: 2020-10-31Updated: 2020-11-12
Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
CompletedNCT04519567
Start: 2020-07-31End: 2021-03-16Updated: 2021-06-30
Phase 2
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
CompletedNCT05579691
Start: 2022-09-21End: 2023-12-04Updated: 2024-11-29
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
RecruitingNCT06447025
Start: 2024-01-25End: 2027-01-01Target: 85Updated: 2026-09-03